JP2018510850A5 - - Google Patents

Download PDF

Info

Publication number
JP2018510850A5
JP2018510850A5 JP2017544584A JP2017544584A JP2018510850A5 JP 2018510850 A5 JP2018510850 A5 JP 2018510850A5 JP 2017544584 A JP2017544584 A JP 2017544584A JP 2017544584 A JP2017544584 A JP 2017544584A JP 2018510850 A5 JP2018510850 A5 JP 2018510850A5
Authority
JP
Japan
Prior art keywords
cancer
compound
pharmaceutically acceptable
acceptable salt
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017544584A
Other languages
English (en)
Japanese (ja)
Other versions
JP6584521B2 (ja
JP2018510850A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2016/050803 external-priority patent/WO2016135582A1/en
Publication of JP2018510850A publication Critical patent/JP2018510850A/ja
Publication of JP2018510850A5 publication Critical patent/JP2018510850A5/ja
Application granted granted Critical
Publication of JP6584521B2 publication Critical patent/JP6584521B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017544584A 2015-02-24 2016-02-15 抗がん剤として有用な置換ヌクレオシド誘導体 Expired - Fee Related JP6584521B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562119932P 2015-02-24 2015-02-24
US62/119,932 2015-02-24
US201562213801P 2015-09-03 2015-09-03
US62/213,801 2015-09-03
US201662279209P 2016-01-15 2016-01-15
US62/279,209 2016-01-15
PCT/IB2016/050803 WO2016135582A1 (en) 2015-02-24 2016-02-15 Substituted nucleoside derivatives useful as anticancer agents

Publications (3)

Publication Number Publication Date
JP2018510850A JP2018510850A (ja) 2018-04-19
JP2018510850A5 true JP2018510850A5 (https=) 2018-10-04
JP6584521B2 JP6584521B2 (ja) 2019-10-02

Family

ID=55451515

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017544584A Expired - Fee Related JP6584521B2 (ja) 2015-02-24 2016-02-15 抗がん剤として有用な置換ヌクレオシド誘導体

Country Status (29)

Country Link
US (1) US10428104B2 (https=)
EP (1) EP3262057B1 (https=)
JP (1) JP6584521B2 (https=)
KR (1) KR20170119705A (https=)
CN (1) CN107278205A (https=)
AU (2) AU2016225133B2 (https=)
BR (1) BR112017017396A2 (https=)
CA (1) CA2921314A1 (https=)
CL (1) CL2017002155A1 (https=)
CO (1) CO2017008403A2 (https=)
CR (1) CR20170384A (https=)
CU (1) CU20170105A7 (https=)
DO (1) DOP2017000195A (https=)
EA (1) EA031895B1 (https=)
ES (1) ES2792899T3 (https=)
GT (1) GT201700189A (https=)
IL (1) IL253637A0 (https=)
MX (1) MX2017010844A (https=)
NI (1) NI201700095A (https=)
PE (1) PE20171449A1 (https=)
PH (1) PH12017501413A1 (https=)
SG (1) SG11201706050WA (https=)
SV (1) SV2017005514A (https=)
TN (1) TN2017000357A1 (https=)
TW (1) TWI622595B (https=)
UA (1) UA118315C2 (https=)
UY (1) UY36564A (https=)
WO (1) WO2016135582A1 (https=)
ZA (1) ZA201705092B (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR104326A1 (es) * 2015-05-04 2017-07-12 Lilly Co Eli Compuestos nucleósidos 5-sustituidos
TWI870767B (zh) 2015-08-26 2025-01-21 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
PE20181894A1 (es) 2016-03-10 2018-12-11 Janssen Pharmaceutica Nv Nuevos analogos de nucleosidos sustituidos para su uso como inhibidores de prmt 5
TN2018000310A1 (en) 2016-03-10 2020-01-16 Janssen Pharmaceutica Nv Substituted nucleoside analogues for use as prmt5 inhibitors
MA46228A (fr) 2016-09-14 2019-07-24 Janssen Pharmaceutica Nv Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
CN109689663B (zh) 2016-09-14 2023-04-14 詹森药业有限公司 Menin-mll相互作用的螺二环抑制剂
CN115626935B (zh) * 2016-10-03 2025-07-15 詹森药业有限公司 用作prmt5抑制剂的单环和双环系统取代的卡巴核苷类似物
BR112019012106A2 (pt) 2016-12-15 2019-10-29 Janssen Pharmaceutica Nv inibidores de azepano de interação menin-mill
WO2018152501A1 (en) * 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018152548A1 (en) * 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
EA201990851A1 (ru) 2017-02-24 2019-09-30 Янссен Фармацевтика Нв Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5
CN110382707A (zh) 2017-02-27 2019-10-25 詹森药业有限公司 生物标志在鉴定将对用prmt5抑制剂治疗有响应的癌症患者中的用途
WO2018160855A1 (en) 2017-03-01 2018-09-07 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
PL3665179T3 (pl) * 2017-08-09 2021-11-29 Prelude Therapeutics, Incorporated Selektywne inhibitory metylotransferazy argininowej białek 5 (prmt5)
WO2019084470A1 (en) * 2017-10-26 2019-05-02 Prelude Therapeutics, Incorporated SELECTIVE INHIBITORS OF THE PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5)
IL275129B2 (en) * 2017-12-08 2023-10-01 Janssen Pharmaceutica Nv Novel spirobicyclic analogues
HUE059945T2 (hu) 2017-12-13 2023-01-28 Lupin Ltd Helyettesített biciklusos heterociklusos vegyületek, mint PRMT5 inhibitorok
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
US10711007B2 (en) 2018-03-14 2020-07-14 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
BR112020018636A2 (pt) * 2018-03-14 2020-12-29 Prelude Therapeutics, Incorporated Inibidores seletivos de proteína arginina metiltransferase 5 (prmt5)
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
EP3833669A4 (en) * 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS
AU2020223058A1 (en) * 2019-02-13 2021-09-09 Prelude Therapeutics, Incorporated Selective inhibitor of protein arginine methyltransferase 5 (PRMT5)
EP3947387B1 (en) * 2019-03-25 2024-10-23 California Institute Of Technology Prmt5 inhibitors and uses thereof
WO2020206299A1 (en) 2019-04-05 2020-10-08 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5
TW202112375A (zh) 2019-06-06 2021-04-01 比利時商健生藥品公司 使用prmt5抑制劑治療癌症之方法
PL3980417T3 (pl) 2019-06-10 2024-03-18 Lupin Limited Inhibitory prmt5
JP7598338B2 (ja) 2019-06-12 2024-12-11 ヤンセン ファーマシューティカ エヌ.ベー. 新規なスピロ二環式中間体
KR102823056B1 (ko) 2019-06-18 2025-06-23 화이자 인코포레이티드 벤즈이속사졸 설폰아마이드 유도체
WO2021055797A1 (en) * 2019-09-18 2021-03-25 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
UA128683C2 (uk) 2019-10-22 2024-09-25 Люпін Лімітед Фармацевтична комбінація на основі інгібіторів prmt5
US20230066014A1 (en) 2019-12-03 2023-03-02 Lupin Limited Substituted nucleoside analogs as prmt5 inhibitors
JP7554829B2 (ja) 2019-12-19 2024-09-20 ヤンセン ファーマシューティカ エヌ.ベー. 置換直鎖スピロ誘導体
CA3192099A1 (en) 2020-08-18 2022-02-24 Incyte Corporation Process and intermediates for preparing a jak inhibitor
CR20230130A (es) 2020-08-18 2023-07-13 Incyte Corp Proceso e intermedios para preparar un inhibidor de jak1
US20240101589A1 (en) * 2020-10-08 2024-03-28 Strom Therapeutics Limited Inhibitors of mettl3
CN112679505B (zh) * 2020-12-25 2022-04-22 杭州澳赛诺生物科技有限公司 一种4-甲基-7H-吡咯并[2,3-d]嘧啶的合成方法
WO2022153161A1 (en) 2021-01-14 2022-07-21 Pfizer Inc. Treatment of cancer using a prmt5 inhibitor
CN118317946A (zh) 2021-07-12 2024-07-09 因赛特公司 用于制备巴瑞替尼的方法和中间体
EP4384519A1 (en) * 2021-08-13 2024-06-19 Albert-Ludwigs-Universität Freiburg Specific small molecule inhibitors that block kmt9 methyltransferase activity and function
WO2024170488A1 (en) 2023-02-13 2024-08-22 Astrazeneca Ab Prmt5 inhibitor for use in cancer therapy
WO2026008533A1 (en) 2024-07-01 2026-01-08 Janssen Pharmaceutica Nv Prmt5 inhibitors for treating adenomas

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646128A (en) * 1989-09-15 1997-07-08 Gensia, Inc. Methods for treating adenosine kinase related conditions
US5864033A (en) * 1989-09-15 1999-01-26 Metabasis Therapeutics, Inc. Adenosine kinase inhibitors
US5795977A (en) * 1989-09-15 1998-08-18 Metabasis Therapeutics, Inc. Water soluble adenosine kinase inhibitors
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
GB9813554D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
US6831069B2 (en) * 1999-08-27 2004-12-14 Ribapharm Inc. Pyrrolo[2,3-d]pyrimidine nucleoside analogs
JP4596913B2 (ja) * 2002-08-15 2010-12-15 ギリアード・パロ・アルト・インコーポレイテッド A1アデノシン受容体の部分および完全アゴニスト
AU2010226466A1 (en) * 2009-03-20 2011-10-20 Alios Biopharma, Inc. Substituted nucleoside and nucleotide analogs
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
US9416154B2 (en) * 2011-07-13 2016-08-16 Merck Sharp & Dohme Corp. 5′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2013044030A1 (en) * 2011-09-23 2013-03-28 Enanta Pharmaceuticals, Inc. 2'-chloroacetylenyl substituted nucleoside derivatives
WO2015200680A2 (en) * 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
AR104326A1 (es) * 2015-05-04 2017-07-12 Lilly Co Eli Compuestos nucleósidos 5-sustituidos
EA201890454A1 (ru) * 2015-08-06 2018-07-31 Чимерикс, Инк. Пирролопиримидиновые нуклеозиды и их аналоги, которые можно использовать в качестве противовирусных средств

Similar Documents

Publication Publication Date Title
JP2018510850A5 (https=)
JP2021523113A5 (https=)
RU2017139515A (ru) Фармацевтически активные соединения в качестве ингибиторов рецепторной тирозинкиназы семейства там
CY1125254T1 (el) Μεθοδοι αγωγης μητρικων ινομυωματων και ενδομητριωσης
JP2021534158A5 (https=)
CN108966651A (zh) 吲哚胺2,3-双加氧酶抑制剂及其制备方法与应用
JP2020517616A5 (https=)
RU2014102935A (ru) Кризотиниб для применения в лечении рака
CN106660974A (zh) 含氨磺酰基的1,2,5‑噁二唑类衍生物、其制备方法及其在医药上的应用
JP2015232006A5 (https=)
CN111051300B (zh) 作为组蛋白脱乙酰基酶1和/或2(hdac1-2)的选择性抑制剂的新杂芳基酰胺衍生物
CN107383014B (zh) 一种1H-吡唑并[3,4-d]嘧啶类化合物及其制备方法和应用
RU2012115851A (ru) Кристаллические формы и сольваты авт-263 для применения в лечении заболеваний, связанных с белком bcl-2
JP2016519685A5 (https=)
RU2015148359A (ru) Хиназолины и азахиназолины - двойные ингибиторы путей ras/raf/mek/erk и pi3k/akt/pten/mtor
JPWO2019212991A5 (https=)
MX2008013204A (es) Uso de biarilcarboxamidas en el tratamiento de trastornos relacionados con la ruta hedgehog.
JP2007530526A5 (https=)
KR102819454B1 (ko) Kras g12d 변이가 존재하는 암 치료를 위한 신규한 화합물 및 이를 이용한 암의 예방 또는 치료용 조성물
JP2011520954A (ja) フェニルまたはピリジニル置換インダゾール誘導体
WO2008001883A1 (en) α-AMINO ACID DERIVATIVE AND PHARMACEUTICAL COMPRISING THE SAME AS ACTIVE INGREDIENT
JP2021518335A5 (https=)
HRP20211652T1 (hr) Pirimidopirimidinoni korisni kao inhibitor wee-1 kinaze
EA200701640A1 (ru) Новые соединения с терапевтическим эффектом
CN108884063A (zh) 吲哚胺2,3-双加氧酶抑制剂及其制备方法与应用